AR121275A1 - Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamento - Google Patents
Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamentoInfo
- Publication number
- AR121275A1 AR121275A1 ARP210100302A ARP210100302A AR121275A1 AR 121275 A1 AR121275 A1 AR 121275A1 AR P210100302 A ARP210100302 A AR P210100302A AR P210100302 A ARP210100302 A AR P210100302A AR 121275 A1 AR121275 A1 AR 121275A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- halogen atom
- optionally substituted
- hydroxy
- cyano
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 108091005625 BRD4 Proteins 0.000 title abstract 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 37
- 125000005843 halogen group Chemical group 0.000 abstract 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 37
- 125000003545 alkoxy group Chemical group 0.000 abstract 36
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 abstract 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 6
- -1 hydroxycarbonyl group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020019227 | 2020-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121275A1 true AR121275A1 (es) | 2022-05-04 |
Family
ID=77199607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100302A AR121275A1 (es) | 2020-02-06 | 2021-02-05 | Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamento |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12102641B2 (https=) |
| EP (1) | EP4105220A4 (https=) |
| JP (3) | JP7419406B2 (https=) |
| KR (1) | KR20220139912A (https=) |
| CN (1) | CN115087658B (https=) |
| AR (1) | AR121275A1 (https=) |
| AU (1) | AU2021215623A1 (https=) |
| BR (1) | BR112022014889A2 (https=) |
| CA (1) | CA3168824C (https=) |
| IL (1) | IL295041A (https=) |
| MX (1) | MX2022009700A (https=) |
| TW (1) | TWI887352B (https=) |
| WO (1) | WO2021157684A1 (https=) |
| ZA (1) | ZA202209896B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7419406B2 (ja) | 2020-02-06 | 2024-01-22 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
| JP2022123408A (ja) * | 2021-02-12 | 2022-08-24 | 株式会社三洋物産 | 遊技機 |
| JP2022123894A (ja) * | 2021-02-12 | 2022-08-25 | 株式会社三洋物産 | 遊技機 |
| JP2022123407A (ja) * | 2021-02-12 | 2022-08-24 | 株式会社三洋物産 | 遊技機 |
| JP2022123893A (ja) * | 2021-02-12 | 2022-08-25 | 株式会社三洋物産 | 遊技機 |
| JP7852736B2 (ja) * | 2022-10-28 | 2026-04-28 | 株式会社村田製作所 | 電子部品および電子部品の実装構造 |
| WO2024251876A1 (en) * | 2023-06-07 | 2024-12-12 | KRæFTENS BEKæMPELSE | PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS |
| CN118359621B (zh) * | 2024-04-16 | 2025-05-16 | 上海陶术生物科技股份有限公司 | 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体 |
| CN120865239B (zh) * | 2025-09-25 | 2025-12-12 | 深圳大学 | 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959361A (en) | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| EP0638560A4 (en) | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| JP2801500B2 (ja) | 1993-07-02 | 1998-09-21 | 株式会社トクヤマ | Ｎ−アルコキシカルボニルアミノ酸の製造方法 |
| CN1109037C (zh) | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN108727380A (zh) * | 2017-04-13 | 2018-11-02 | 中国科学院上海药物研究所 | 一种brd4抑制剂及其制备和应用 |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| EP3723757A4 (en) | 2017-12-14 | 2021-08-18 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE TYPE DEGRADATION AGENTS RECRUITING DCAF15 |
| US11629152B2 (en) * | 2018-03-30 | 2023-04-18 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
| EP3819305A4 (en) * | 2018-07-04 | 2022-04-06 | Mitsubishi Tanabe Pharma Corporation | AMIDE COMPOUND WITH BET PROTEOLYSIS-INDUCING ACTIVITY AND MEDICAL USE THEREOF |
| JP7140273B2 (ja) | 2019-04-09 | 2022-09-21 | 株式会社村田製作所 | 電池 |
| JP7419406B2 (ja) * | 2020-02-06 | 2024-01-22 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
-
2021
- 2021-02-05 JP JP2021575876A patent/JP7419406B2/ja active Active
- 2021-02-05 MX MX2022009700A patent/MX2022009700A/es unknown
- 2021-02-05 CN CN202180012524.0A patent/CN115087658B/zh active Active
- 2021-02-05 TW TW110104483A patent/TWI887352B/zh active
- 2021-02-05 IL IL295041A patent/IL295041A/en unknown
- 2021-02-05 WO PCT/JP2021/004231 patent/WO2021157684A1/ja not_active Ceased
- 2021-02-05 AR ARP210100302A patent/AR121275A1/es unknown
- 2021-02-05 US US17/796,258 patent/US12102641B2/en active Active
- 2021-02-05 EP EP21750647.6A patent/EP4105220A4/en active Pending
- 2021-02-05 KR KR1020227030071A patent/KR20220139912A/ko active Pending
- 2021-02-05 BR BR112022014889A patent/BR112022014889A2/pt unknown
- 2021-02-05 AU AU2021215623A patent/AU2021215623A1/en active Pending
- 2021-02-05 CA CA3168824A patent/CA3168824C/en active Active
-
2022
- 2022-09-05 ZA ZA2022/09896A patent/ZA202209896B/en unknown
-
2023
- 2023-07-20 US US18/355,554 patent/US11890288B2/en active Active
-
2024
- 2024-01-10 JP JP2024001990A patent/JP7681737B2/ja active Active
- 2024-08-06 US US18/795,713 patent/US20240390387A1/en active Pending
-
2025
- 2025-05-12 JP JP2025079628A patent/JP2025122015A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220139912A (ko) | 2022-10-17 |
| US20230146717A1 (en) | 2023-05-11 |
| TWI887352B (zh) | 2025-06-21 |
| ZA202209896B (en) | 2025-12-17 |
| MX2022009700A (es) | 2022-09-07 |
| US12102641B2 (en) | 2024-10-01 |
| WO2021157684A1 (ja) | 2021-08-12 |
| EP4105220A4 (en) | 2024-02-21 |
| IL295041A (en) | 2022-09-01 |
| AU2021215623A1 (en) | 2022-08-25 |
| CA3168824C (en) | 2024-10-22 |
| TW202140498A (zh) | 2021-11-01 |
| US20230364105A1 (en) | 2023-11-16 |
| CN115087658B (zh) | 2025-02-28 |
| JPWO2021157684A1 (https=) | 2021-08-12 |
| JP2024041888A (ja) | 2024-03-27 |
| JP7419406B2 (ja) | 2024-01-22 |
| CA3168824A1 (en) | 2021-08-12 |
| EP4105220A1 (en) | 2022-12-21 |
| JP2025122015A (ja) | 2025-08-20 |
| CN115087658A (zh) | 2022-09-20 |
| US11890288B2 (en) | 2024-02-06 |
| JP7681737B2 (ja) | 2025-05-22 |
| BR112022014889A2 (pt) | 2022-09-20 |
| US20240390387A1 (en) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121275A1 (es) | Compuesto de sulfonamida o sulfinamida que tiene acción inhibidora de la proteína brd4 y su uso como medicamento | |
| AR107966A2 (es) | Derivados de pirimidina y piridina inhibidores de la proteína quinasa | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR055116A1 (es) | Compuestos aromaticos como agentes terapeuticos para diabetes y composiciones farmaceuticas que los contienen. | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| ES2577382T3 (es) | Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos | |
| CY1111601T1 (el) | Παραγωγα καρβοξαμιδιων της τριαζολοπυριδινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| AR114239A1 (es) | Oxadiazoles | |
| ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| AR118082A1 (es) | Inhibidores de enzimas | |
| AR118081A1 (es) | Inhibidores de enzimas | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| AR121744A1 (es) | MODULADORES DE a 1-ANTITRIPSINA | |
| AR052266A1 (es) | Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos | |
| AR089788A1 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |